

## Refine Search

### Search Results -

Term	Documents
13.CLM..PGPB,USPT,EPAB,JPAB,DWPI.	11
(L13.CLM. ).PGPB,USPT,EPAB,JPAB,DWPI.	11

Database:

US Pre-Grant Publication Full-Text Database  
 US Patents Full-Text Database  
 US OCR Full-Text Database  
 EPO Abstracts Database  
 JPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

Search:

L14





### Search History

DATE: Tuesday, March 13, 2007   
 [Purge Queries](#)   
 [Printable Copy](#)   
 [Create Case](#)

#### Set Name Query

side by side

#### Hit Count Set Name

result set

*DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ*

L14    L13.clm.    11    L14

L13    (cd18 or ccr2)same (stenosis or restenosis)    89    L13

*DB=PGPB; PLUR=YES; OP=ADJ*

L12    (cd18 or ccr2)same (stenosis or restenosis)    42    L12

L11    L8    122    L11

*DB=USPT; PLUR=YES; OP=ADJ*

L10    L8    55    L10

*DB=EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ*

L9    L8    7    L9

*DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ*

L8    (cd18)same (antibod\$) and (stenosis or restenosis)    184    L8

L7    (cd18) and (ccr2) and (stenosis or restenosis)    55    L7

L6    L5 and (stenosis or restenosis)    34    L6

<u>L5</u>	(L1 or L2) and (ccr2 or chemokine\$)	54	<u>L5</u>
<u>L4</u>	L3 and (stenosis or restenosis)	11	<u>L4</u>
<u>L3</u>	(L1 or L2) and (cd18)	18	<u>L3</u>
<u>L2</u>	rao.in.	10067	<u>L2</u>
<u>L1</u>	horvath.in.	3270	<u>L1</u>

END OF SEARCH HISTORY

## Refine Search

### Search Results -

Term	Documents
13.CLM..PGPB,USPT,EPAB,JPAB,DWPI.	11
(L13.CLM. ).PGPB,USPT,EPAB,JPAB,DWPI.	11

Database:

US Pre-Grant Publication Full-Text Database  
 US Patents Full-Text Database  
 US OCR Full-Text Database  
 EPO Abstracts Database  
 JPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

Search:

L14





### Search History

DATE: Tuesday, March 13, 2007   
 [Purge Queries](#)   
 [Printable Copy](#)   
 [Create Case](#)

#### Set Name Query

side by side

#### Hit Count Set Name

result set

*DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ*

L14    L13.clm.    11    L14

L13    (cd18 or ccr2)same (stenosis or restenosis)    89    L13

*DB=PGPB; PLUR=YES; OP=ADJ*

L12    (cd18 or ccr2)same (stenosis or restenosis)    42    L12

L11    L8    122    L11

*DB=USPT; PLUR=YES; OP=ADJ*

L10    L8    55    L10

*DB=EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ*

L9    L8    7    L9

*DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ*

L8    (cd18)same (antibod\$) and (stenosis or restenosis)    184    L8

L7    (cd18) and (ccr2) and (stenosis or restenosis)    55    L7

L6    L5 and (stenosis or restenosis)    34    L6

<u>L5</u>	(L1 or L2) and (ccr2 or chemokine\$)	54	<u>L5</u>
<u>L4</u>	L3 and (stenosis or restenosis)	11	<u>L4</u>
<u>L3</u>	(L1 or L2) and (cd18)	18	<u>L3</u>
<u>L2</u>	rao.in.	10067	<u>L2</u>
<u>L1</u>	horvath.in.	3270	<u>L1</u>

END OF SEARCH HISTORY

begin 5,73,155,399

13mar07 14:32:26 User208760 Session D2836.2

\$0.00 0.115 DialUnits File410

\$0.00 Estimated cost File410

\$0.03 TELNET

\$0.03 Estimated cost this search

\$4.68 Estimated total session cost 1.370 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:BIOSIS Previews(R) 1926-2007/Mar W1

(c) 2007 The Thomson Corporation

\*File 5: BIOSIS has been enhanced with archival data. Please see  
HELP NEWS 5 for information.

File 73:EMBASE 1974-2007/Mar 13

(c) 2007 Elsevier B.V.

File 155:MEDLINE(R) 1950-2007/Mar 09

(c) format only 2007 Dialog

File 399:CA SEARCH(R) 1967-2007/UD=14612

(c) 2007 American Chemical Society

\*File 399: Use is subject to the terms of your user/customer agreement.  
IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.

Set Items Description

? e .au=horvath chris ?

Ref	Items	Index-term
E1	1	AU=HORVATH CECELIA
E2	7	AU=HORVATH CECILIA
E3	0	*AU=HORVATH CHRIS ?
E4	1	AU=HORVATH CHRISTINE M
E5	19	AU=HORVATH CHRISTOPHER
E6	3	AU=HORVATH CHRISTOPHER D
E7	7	AU=HORVATH CHRISTOPHER J
E8	4	AU=HORVATH CHRISTOPHER R
E9	1	AU=HORVATH CLOTILDE
E10	8	AU=HORVATH CS
E11	13	AU=HORVATH CS.
E12	99	AU=HORVATH CSABA

Enter P or PAGE for more

? s e5-e8

19	AU=HORVATH CHRISTOPHER
3	AU=HORVATH CHRISTOPHER D
7	AU=HORVATH CHRISTOPHER J
4	AU=HORVATH CHRISTOPHER R

S1 33 E5-E8

? e au=rao pat ?

Ref	Items	Index-term
E1	2	AU=RAO PASUPULETI VENKATA
E2	1	AU=RAO PAT
E3	0	*AU=RAO PAT ?
E4	1	AU=RAO PAT M
E5	1	AU=RAO PATANJALI
E6	1	AU=RAO PATCHA R
E7	1	AU=RAO PATCHALA J R MOHAN
E8	5	AU=RAO PATRICIA
E9	2	AU=RAO PATRICIA A
E10	13	AU=RAO PATRICIA E
E11	1	AU=RAO PATRICK
E12	14	AU=RAO PATRICK M

Enter P or PAGE for more

? s e8-e10

5 AU=RAO PATRICIA  
2 AU=RAO PATRICIA A  
13 AU=RAO PATRICIA E

S2 20 E8-E10

? s (s1 or s2) and (cd18 or ccr2)

33 S1  
20 S2  
16710 CD18  
4472 CCR2

S3 9 (S1 OR S2) AND (CD18 OR CCR2)

? rd s3

S4 8 RD S3 (unique items)

? t s4/3/all

4/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

17893792 BIOSIS NO.: 200400264549

Recombinant anti-CCR2 antibodies and methods of use therefor

AUTHOR: LaRosa Gregory J (Reprint); Horvath Christopher; Newman  
Walter; Jones S Tarran; O'Brien Siobhan H; O'Keefe Theresa

AUTHOR ADDRESS: Radlett, UK\*\*UK

JOURNAL: Official Gazette of the United States Patent and Trademark Office  
Patents 1281 (4): Apr. 27, 2004 2004

MEDIUM: e-file

PATENT NUMBER: US 6727349 PATENT DATE GRANTED: April 27, 2004 20040427

PATENT CLASSIFICATION: 530-3873 PATENT ASSIGNEE: Millennium

Pharmaceuticals, Inc. PATENT COUNTRY: USA

ISSN: 0098-1133 (ISSN print)

DOCUMENT TYPE: Patent

RECORD TYPE: Abstract

LANGUAGE: English

4/3/2 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

17806947 BIOSIS NO.: 200400177704

Humanized anti-CCR2 antibodies and methods of use therefor

AUTHOR: LaRosa Gregory J (Reprint); Horvath Christopher; Newman  
Walter; Jones S Tarran; O'Brien Siobhan H; O'Keefe Theresa

AUTHOR ADDRESS: Newton, MA, USA\*\*USA

JOURNAL: Official Gazette of the United States Patent and Trademark Office  
Patents 1279 (4): Feb. 24, 2004 2004

MEDIUM: e-file

PATENT NUMBER: US 6696550 PATENT DATE GRANTED: February 24, 2004 20040224

PATENT CLASSIFICATION: 530-38823 PATENT ASSIGNEE: Millennium

Pharmaceuticals, Inc. PATENT COUNTRY: USA

ISSN: 0098-1133 (ISSN print)

DOCUMENT TYPE: Patent

RECORD TYPE: Abstract

LANGUAGE: English

4/3/3 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

17679639 BIOSIS NO.: 200400060396  
Method of inhibiting stenosis and restenosis  
AUTHOR: Horvath Christopher J (Reprint); Rao Patricia E  
AUTHOR ADDRESS: Taunton, MA, USA\*\*USA  
JOURNAL: Official Gazette of the United States Patent and Trademark Office  
Patents 1277 (3): Dec. 16, 2003 2003  
MEDIUM: e-file  
PATENT NUMBER: US 6663863 PATENT DATE GRANTED: December 16, 2003 20031216  
PATENT CLASSIFICATION: 424-1441 PATENT ASSIGNEE: Millennium  
Pharmaceuticals, Inc. PATENT COUNTRY: USA  
ISSN: 0098-1133 (ISSN print)  
DOCUMENT TYPE: Patent  
RECORD TYPE: Abstract  
LANGUAGE: English

4/3/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2007 The Thomson Corporation. All rts. reserv.

16627848 BIOSIS NO.: 200200221359  
Targeting CCR2 or CD18 inhibits experimental in-stent  
restenosis in primates: Inhibitory potential depends on type of injury  
and leukocytes targeted  
AUTHOR: Horvath Christopher; Welt Frederick G P (Reprint); Nedelman  
Mark; Rao Patricia; Rogers Campbell  
AUTHOR ADDRESS: Harvard-MIT Division of Health Sciences and Technology,  
MIT, 16-343, Cambridge, MA, 02139, USA\*\*USA  
JOURNAL: Circulation Research 90 (4): p488-494 March 8, 2002 2002  
MEDIUM: print  
ISSN: 0009-7330  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

4/3/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2007 The Thomson Corporation. All rts. reserv.

16625478 BIOSIS NO.: 200200218989  
Anti-CCR2 antibodies and methods of use therefor  
AUTHOR: LaRosa Gregory J (Reprint); Horvath Christopher; Newman  
Walter  
AUTHOR ADDRESS: West Roxbury, MA, USA\*\*USA  
JOURNAL: Official Gazette of the United States Patent and Trademark Office  
Patents 1256 (1): Mar. 5, 2002 2002  
MEDIUM: e-file  
PATENT NUMBER: US 6352832 PATENT DATE GRANTED: March 05, 2002 20020305  
PATENT CLASSIFICATION: 435-71 PATENT ASSIGNEE: Millennium Pharmaceuticals,  
Inc. PATENT COUNTRY: USA  
ISSN: 0098-1133  
DOCUMENT TYPE: Patent  
RECORD TYPE: Abstract  
LANGUAGE: English

4/3/6 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2007 The Thomson Corporation. All rts. reserv.

15896967 BIOSIS NO.: 200100068806

Targeting CCR-2 or CD18 inhibits experimental in-stent restenosis in primates. Inhibitory potential depends on type of injury and leukocytes targeted

AUTHOR: Welt Frederick G P (Reprint); Horvath Christopher; Nedelman Mark; Rao Patricia; Rogers Campbell

AUTHOR ADDRESS: Brigham and Women's Hosp, Boston, MA, USA\*\*USA

JOURNAL: Circulation 102 (18 Supplement): pII.247 October 31, 2000 2000

MEDIUM: print

CONFERENCE/MEETING: Abstracts from American Heart Association Scientific Sessions 2000 New Orleans, Louisiana, USA November 12-15, 2000; 20001112

SPONSOR: American Heart Association

ISSN: 0009-7322

DOCUMENT TYPE: Meeting; Meeting Poster

RECORD TYPE: Citation

LANGUAGE: English

4/3/7 (Item 7 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

14119855 BIOSIS NO.: 199799753915

High expression of the chemokine receptor CCR3 in human blood basophils.

Role in activation by eotaxin, MCP-4 and other chemokines

AUTHOR: Uguccioni Mariagrazia; Mackay Charles R; Ochensberger Brigitte;

Loetscher Pius; Rhis Silvia; Larosa Gregory J; Rao Patricia; Ponath

Paul D; Baggiolini Marco; Dahinden Clemens A (Reprint)

AUTHOR ADDRESS: Inst. Immunol. Allergol., Univ. Hosp., Inselspital, CH-3010 Bern, Switzerland\*\*Switzerland

JOURNAL: Journal of Clinical Investigation 100 (5): p1137-1143 1997 1997

ISSN: 0021-9738

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

4/3/8 (Item 8 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

12620101 BIOSIS NO.: 199598087934

Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators

AUTHOR: Derian Claudia K (Reprint); Santulli Rosemary J; Rao Patricia

E; Solomon Howard F; Barrett John A

AUTHOR ADDRESS: R.W. Johnson Pharmaceutical Research Inst., Welsh and

McKean Roads, Spring House, PA 19477, USA\*\*USA

JOURNAL: Journal of Immunology 154 (1): p308-317 1995 1995

ISSN: 0022-1767

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

? t s4/7/4

4/7/4 (Item 4 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

16627848 BIOSIS NO.: 200200221359

Targeting CCR2 or CD18 inhibits experimental in-stent

restenosis in primates: Inhibitory potential depends on type of injury



and leukocytes targeted  
AUTHOR: Horvath Christopher; Welt Frederick G P (Reprint); Nedelman  
Mark; Rao Patricia; Rogers Campbell  
AUTHOR ADDRESS: Harvard-MIT Division of Health Sciences and Technology,  
MIT, 16-343, Cambridge, MA, 02139, USA\*\*USA  
JOURNAL: Circulation Research 90 (4): p488-494 March 8, 2002 2002  
MEDIUM: print  
ISSN: 0009-7330  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: A central role for leukocytes in neointimal hyperplasia after arterial injury is suspected. However, the relative importance of neutrophils and monocytes in balloon or stent-induced injury are not well understood, and mechanistic targeting of leukocyte recruitment or function is crude. We determined the temporal and spatial distribution of different leukocytes after balloon and stent-induced injury in primate iliac arteries. Based on these data, we targeted neutrophil and monocyte recruitment selectively after angioplasty or stent implantation and demonstrated that monocyte-specific blockade achieved via blockade of the MCP-1 receptor CCR2, was effective at reducing neointimal hyperplasia after stenting. In contrast, combined neutrophil and monocyte blockade achieved by targeting the leukocyte beta2-integrin beta-subunit CD18 was required to reduce neointimal hyperplasia after balloon injury. Distinct patterns of leukocyte infiltration in balloon versus stent-injured arteries predict distinct mechanisms for antiinflammatory strategies targeting neutrophils or monocytes in primates and may assist design of effective clinical strategies for optimizing vascular interventions.

? s (cd18) and (ccr2) and (stenosis or restenosis)  
16710 CD18  
4472 CCR2  
254561 STENOSIS  
46086 RESTENOSIS  
S5 7 (CD18) AND (CCR2) AND (STENOSIS OR RESTENOSIS)  
? rd s5  
S6 4 RD S5 (unique items)  
? t s6/3/all

6/3/1 (Item 1 from file: 5)  
DIALOG(R) File 5: Biosis Previews(R)  
(c) 2007 The Thomson Corporation. All rts. reserv.

17679639 BIOSIS NO.: 200400060396  
Method of inhibiting stenosis and restenosis  
AUTHOR: Horvath Christopher J (Reprint); Rao Patricia E  
AUTHOR ADDRESS: Taunton, MA, USA\*\*USA  
JOURNAL: Official Gazette of the United States Patent and Trademark Office  
Patents 1277 (3): Dec. 16, 2003 2003  
MEDIUM: e-file  
PATENT NUMBER: US 6663863 PATENT DATE GRANTED: December 16, 2003 20031216  
PATENT CLASSIFICATION: 424-1441 PATENT ASSIGNEE: Millennium  
Pharmaceuticals, Inc. PATENT COUNTRY: USA  
ISSN: 0098-1133 (ISSN print)  
DOCUMENT TYPE: Patent  
RECORD TYPE: Abstract  
LANGUAGE: English

6/3/2 (Item 2 from file: 5)  
DIALOG(R) File 5: Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

16627848 BIOSIS NO.: 200200221359

Targeting CCR2 or CD18 inhibits experimental in-stent  
restenosis in primates: Inhibitory potential depends on type of  
injury and leukocytes targeted

AUTHOR: Horvath Christopher; Welt Frederick G P (Reprint); Nedelman Mark;  
Rao Patricia; Rogers Campbell

AUTHOR ADDRESS: Harvard-MIT Division of Health Sciences and Technology,  
MIT, 16-343, Cambridge, MA, 02139, USA\*\*USA

JOURNAL: Circulation Research 90 (4): p488-494 March 8, 2002 2002

MEDIUM: print

ISSN: 0009-7330

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

6/3/3 (Item 1 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2007 American Chemical Society. All rts. reserv.

137168272 CA: 137(12)168272m PATENT

Antibodies and fragments specific to CD18 antigen or chemokine receptor  
CCR2 for inhibiting stenosis and restenosis

INVENTOR(AUTHOR): Horvath, Christopher J.; Rao, Patricia E.

LOCATION: USA

ASSIGNEE: Millennium Pharmaceuticals, Inc.

PATENT: U.S. Pat. Appl. Publ. ; US 20020106369 A1 DATE: 20020808

APPLICATION: US 809739 (20010315) \*US 528267 (20000317)

PAGES: 59 pp., Cont.-in-part of U. S. Ser. No. 528,267, abandoned.

CODEN: USXXCO LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: 424131100; A61K-039/395A

6/3/4 (Item 2 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2007 American Chemical Society. All rts. reserv.

135283193 CA: 135(20)283193g PATENT

Method of inhibiting stenosis and restenosis using CD18 or CCR2  
antibodies

INVENTOR(AUTHOR): Horvath, Christopher J.; Rao, Patricia E.

LOCATION: USA

ASSIGNEE: Millennium Pharmaceuticals, Inc.

PATENT: PCT International ; WO 200170266 A2 DATE: 20010927

APPLICATION: WO 2001US8266 (20010315) \*US 528267 (20000317)

PAGES: 108 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-039/395A; A61P-009/10B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM;  
HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV;  
MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK;  
SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD;  
RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG  
; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT;  
SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG  
? ds

Set Items Description

S1 33 E5-E8  
 S2 20 E8-E10  
 S3 9 (S1 OR S2) AND (CD18 OR CCR2)  
 S4 8 RD S3 (unique items)  
 S5 7 (CD18) AND (CCR2) AND (STENOSIS OR RESTENOSIS)  
 S6 4 RD S5 (unique items)  
 ? s (cd18)(10n)(antibod? or antagoni?) and (stenosis or restenosis)  
     16710 CD18  
     2207531 ANTIBOD?  
     1277282 ANTAGONI?  
         4270 CD18(10N)(ANTIBOD? OR ANTAGONI?)  
         254561 STENOSIS  
         46086 RESTENOSIS  
 S7 25 (CD18)(10N)(ANTIBOD? OR ANTAGONI?) AND (STENOSIS OR  
     RESTENOSIS)  
 ? rd s7  
     S8 17 RD S7 (unique items)  
 ? t s8/3/all

8/3/1 (Item 1 from file: 5)  
 DIALOG(R)File 5:Biosis Previews(R)  
 (c) 2007 The Thomson Corporation. All rts. reserv.

17679639 BIOSIS NO.: 200400060396  
 Method of inhibiting stenosis and restenosis  
 AUTHOR: Horvath Christopher J. (Reprint); Rao Patricia E  
 AUTHOR ADDRESS: Taunton, MA, USA\*\*USA  
 JOURNAL: Official Gazette of the United States Patent and Trademark Office  
 Patents 1277 (3): Dec. 16, 2003 2003  
 MEDIUM: e-file  
 PATENT NUMBER: US 6663863 PATENT DATE GRANTED: December 16, 2003 20031216  
 PATENT CLASSIFICATION: 424-1441 PATENT ASSIGNEE: Millennium  
 Pharmaceuticals, Inc. PATENT COUNTRY: USA  
 ISSN: 0098-1133 (ISSN print)  
 DOCUMENT TYPE: Patent  
 RECORD TYPE: Abstract  
 LANGUAGE: English

8/3/2 (Item 2 from file: 5)  
 DIALOG(R)File 5:Biosis Previews(R)  
 (c) 2007 The Thomson Corporation. All rts. reserv.

15819149 BIOSIS NO.: 200000537462  
 Anti-CD18 antibody blocks leucocyte trafficking in porcine  
 coronary arteries following PTCA  
 AUTHOR: Malik N (Reprint); Holt C M; Gunn J; Hellewell P; Cumberland D C;  
 Crossman D C  
 AUTHOR ADDRESS: Cardiovascular Research Group, Northern General Hospital,  
 Sheffield, UK\*\*UK  
 JOURNAL: European Heart Journal 21 (Abstract Supplement): p284  
 August-September, 2000 2000  
 MEDIUM: print  
 CONFERENCE/MEETING: XXII Congress of the European Society of Cardiology  
 Amsterdam, Netherlands August 26-30, 2000; 20000826  
 SPONSOR: European Society of Cardiology  
 ISSN: 0195-668X  
 DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster  
 RECORD TYPE: Citation  
 LANGUAGE: English

8/3/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2007 The Thomson Corporation. All rts. reserv.

13910318 BIOSIS NO.: 199799544378  
Inhibition of leucocyte and platelet adhesion reduces neointimal  
hyperplasia after arterial injury  
AUTHOR: Golino Paolo (Reprint); Ambrosio Giuseppe; Ragni Massimo; Cirillo  
Plinio; Esposito Nicolino; Willerson James T; Rothlein Robert; Petrucci  
Luisa; Condorelli Mario; Chiareillo Massimo; Buja L Maximilan  
AUTHOR ADDRESS: Div. Cardiol., 2nd Sch. Med., Univ. Naples, Via S. Pansini  
5, 80131 Naples, Italy\*\*Italy  
JOURNAL: Thrombosis and Haemostasis 77 (4): p783-788 1997 1997  
ISSN: 0340-6245  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

8/3/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2007 The Thomson Corporation. All rts. reserv.

13160645 BIOSIS NO.: 199698628478  
Role of leukocytes in neointimal formation after balloon angioplasty in the  
rabbit atherosclerotic model  
AUTHOR: Guzman Luis A; Forudi Farhad; Villa Augusto E; Topol Eric J  
(Reprint)  
AUTHOR ADDRESS: Cleveland Clin. Foundation, 9500 Euclid Ave., Desk F-25,  
Cleveland, OH 44195-5066, USA\*\*USA  
JOURNAL: Coronary Artery Disease 6 (9): p693-701 1995 1995  
ISSN: 0954-6928  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

8/3/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2007 The Thomson Corporation. All rts. reserv.

12193575 BIOSIS NO.: 199497214860  
Effect of anti-CD18 adhesion glycoprotein monoclonal antibody  
on restenosis following balloon angioplasty in the rabbit  
atherosclerosis model  
AUTHOR: Guzman Luis A; Villa Augusto E; Forudi Farhad; Rothlein Robert;  
Topol Eric J  
AUTHOR ADDRESS: Cleve. Clin. Found., Cleveland, OH, USA\*\*USA  
JOURNAL: Journal of the American College of Cardiology 0 (SPEC. ISSUE): p  
20A 1994 1994  
CONFERENCE/MEETING: 43rd Annual Scientific Session of the American College  
of Cardiology Atlanta, Georgia, USA March 13-17, 1994; 19940313  
ISSN: 0735-1097  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Citation  
LANGUAGE: English

8/3/6 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2007 The Thomson Corporation. All rts. reserv.

11194133 BIOSIS NO.: 199293037024

ROLE OF GRANULOCYTES IN ENDOTHELIAL INJURY IN CORONARY HEART DISEASE IN HUMANS

AUTHOR: RICEVUTI G (Reprint); MAZZONE A; PASOTTI D; DE SERVI S; SPECCHIA G

AUTHOR ADDRESS: IST PATOLOGIA MED I, UNIV PAVIA, IRCCS POLICLINICO SAN MATTEO, PIAZZALE GOLGI 2, 27100, IRCCS PLICLINICO SAN MATTEO, PIAZZLE GOLGI 2, 27100 PAVIA, ITALY\*\*ITALY

JOURNAL: Atherosclerosis 91 (1-2): p1-14 1991

ISSN: 0021-9150

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

8/3/7 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2007 Elsevier B.V. All rts. reserv.

13087050 EMBASE No: 2005148161

Therapeutic intervention in inflammatory diseases: A time and place for anti-adhesion therapy

Norman M.U.; Kubes P.

Dr. P. Kubes, Department of Physiology/Biophysics, Immunology Research Group, University of Calgary, 3330 Hospital Drive N.W., Calgary, Alta. T2N 4N1 Canada

AUTHOR EMAIL: pkubes@ucalgary.ca

Microcirculation ( MICROCIRCULATION ) (United States) 2005, 12/1 (91-98)

CODEN: MROCE ISSN: 1073-9688

DOCUMENT TYPE: Journal ; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 67

8/3/8 (Item 2 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2007 Elsevier B.V. All rts. reserv.

12990559 EMBASE No: 2005050598

Tc-99m sestamibi infarct size as a surrogate endpoint

Gibbons R.J.; Miller T.D.

Dr. R.J. Gibbons, Nuclear Cardiology Laboratory, Mayo Clinic, 200 First St. SW, Rochester, MN 55905 United States

AUTHOR EMAIL: gibbons.raymond@mayo.edu

Journal of Nuclear Cardiology ( J. NUCL. CARDIOL. ) (United States) 2005, 12/1 (12-19)

CODEN: JNCAE ISSN: 1071-3581

PUBLISHER ITEM IDENTIFIER: S1071358104004593

DOCUMENT TYPE: Journal ; Editorial

LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 46

8/3/9 (Item 3 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2007 Elsevier B.V. All rts. reserv.

12217567 EMBASE No: 2003330343

Adhesion of monocytes to medical steel as used for vascular stents is mediated by the integrin receptor Mac-1 (CD11b/CD18; alphaSUBM betaSUB2) and can be inhibited by semiconductor coating

Schuler P.; Assefa D.; Ylanne J.; Basler N.; Olschewski M.; Ahrens I.;

Nordt T.; Bode C.; Peter K.  
Dr. K. Peter, Department of Cardiology/Angiology, University of Freiburg,  
Hugstetter Str. 55, 79106 Freiburg Germany  
AUTHOR EMAIL: peterkh@medizin.ukl.uni-freiburg.de  
Cell Communication and Adhesion ( CELL COMMUN. ADHES. ) (United States)  
2003, 10/1 (17-26)  
CODEN: CCAEB ISSN: 1541-9061  
DOCUMENT TYPE: Journal ; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 32

8/3/10 (Item 4 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2007 Elsevier B.V. All rts. reserv.

11641248 EMBASE No: 2002214275  
Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in  
primates: Inhibitory potential depends on type of injury and leukocytes  
targeted  
Horvath C.; Welt F.G.P.; Nedelman M.; Rao P.; Rogers C.  
Dr. F.G.P. Welt, Harvard-MIT Div. Hlth. Sci./Technol., MIT. 16-343,  
Cambridge, MA 02139 United States  
AUTHOR EMAIL: welt@mediaone.net  
Circulation Research ( CIRC. RES. ) (United States) 08 MAR 2002, 90/4  
(488-494)  
CODEN: CIRUA ISSN: 0009-7330  
DOCUMENT TYPE: Journal ; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 35

8/3/11 (Item 5 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2007 Elsevier B.V. All rts. reserv.

07410615 EMBASE No: 1998305613  
A mAb to the betainf 2-leukocyte integrin Mac-1 (CD11b/CD18) reduces  
intimal thickening after angioplasty or stent implantation in rabbits  
Rogers C.; Edelman E.R.; Simon D.I.  
C. Rogers, Cardiovascular Division, Brigham and Women's Hospital, 75  
Francis Street, Boston, MA 02115 United States  
AUTHOR EMAIL: cdrogers@bics.bwh.harvard.edu  
Proceedings of the National Academy of Sciences of the United States of  
America ( PROC. NATL. ACAD. SCI. U. S. A. ) (United States) 18 AUG 1998  
, 95/17 (10134-10139)  
CODEN: PNAS A ISSN: 0027-8424  
DOCUMENT TYPE: Journal; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 58

8/3/12 (Item 1 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2007 Dialog. All rts. reserv.

13089612 PMID: 16100700  
Rovelizumab (ICOS Corp).  
Jones R  
Trinity Cottage, Killiney Hill Road, Killiney, Co Dublin, Ireland,  
rjj101@excite.com  
IDrugs - the investigational drugs journal (England) Apr 2000, 3 (4)

p442-6, ISSN 1369-7056--Print Journal Code: 100883655  
Publishing Model Print  
Document type: Journal Article  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: PubMed not MEDLINE

8/3/13 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

11881678 PMID: 9707613

A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits.

Rogers C; Edelman E R; Simon D I

Department of Medicine, Cardiac Catheterization Laboratory and Coronary Care Unit, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. cdrogers@bics.bwh.harvard.edu

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Aug 18 1998, 95 (17) p10134-9, ISSN 0027-8424  
--Print Journal Code: 7505876

Contract/Grant No.: GM/HL49039; GM; NIGMS; HL02768; HL; NHLBI; HL03104; HL; NHLBI; +

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

8/3/14 (Item 3 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

11808972 PMID: 9633931

Role of polymorphonuclear leukocytes in collar-induced intimal thickening in the rabbit carotid artery.

Van Put D J; Van Osselaer N; De Meyer G R; Andries L J; Kockx M M; De Clerck L S; Bult H

Division of Pharmacology, University of Antwerp (UIA), Wilrijk, Belgium. Arteriosclerosis, thrombosis, and vascular biology (UNITED STATES) Jun 1998, 18 (6) p915-21, ISSN 1079-5642--Print Journal Code: 9505803

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

8/3/15 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2007 American Chemical Society. All rts. reserv.

137168272 CA: 137(12)168272m PATENT

Antibodies and fragments specific to CD18 antigen or chemokine receptor CCR2 for inhibiting stenosis and restenosis

INVENTOR(AUTHOR): Horvath, Christopher J.; Rao, Patricia E.

LOCATION: USA

ASSIGNEE: Millennium Pharmaceuticals, Inc.

PATENT: U.S. Pat. Appl. Publ. ; US 20020106369 A1 DATE: 20020808

APPLICATION: US 809739 (20010315) \*US 528267 (20000317)

PAGES: 59 pp., Cont.-in-part of U. S. Ser. No. 528,267, abandoned.  
CODEN: USXXCO LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: 424131100; A61K-039/395A

8/3/16 (Item 2 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

135283193 CA: 135(20)283193g PATENT  
Method of inhibiting stenosis and restenosis using CD18 or CCR2  
antibodies  
INVENTOR(AUTHOR): Horvath, Christopher J.; Rao, Patricia E.  
LOCATION: USA  
ASSIGNEE: Millennium Pharmaceuticals, Inc.  
PATENT: PCT International ; WO 200170266 A2 DATE: 20010927  
APPLICATION: WO 2001US8266 (20010315) \*US 528267 (20000317)  
PAGES: 108 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-039/395A; A61P-009/10B  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM;  
HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV;  
MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK;  
SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD;  
RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG  
; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT;  
SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

8/3/17 (Item 3 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

135271896 CA: 135(19)271896a PATENT  
CD18-binding antibodies inhibit stenosis-related disorders  
INVENTOR(AUTHOR): Horvath, Christopher J.  
LOCATION: USA  
ASSIGNEE: Millennium Pharmaceuticals, Inc.  
PATENT: PCT International ; WO 200170260 A1 DATE: 20010927  
APPLICATION: WO 2001US8383 (20010316) \*US 531088 (20000317)  
PAGES: 80 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-039/00A; A61K-039/395B; C07K-016/00B; C07K-016/28B  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM;  
HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV;  
MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK;  
SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD;  
RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG  
; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT;  
SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG  
? t s8/7/8

8/7/8 (Item 2 from file: 73)  
DIALOG(R) File 73:EMBASE  
(c) 2007 Elsevier B.V. All rts. reserv.

12990559 EMBASE No: 2005050598  
Tc-99m sestamibi infarct size as a surrogate endpoint  
Gibbons R.J.; Miller T.D.



Dr. R.J. Gibbons, Nuclear Cardiology Laboratory, Mayo Clinic, 200 First St. SW, Rochester, MN 55905 United States  
 AUTHOR EMAIL: gibbons.raymond@mayo.edu  
 Journal of Nuclear Cardiology ( J. NUCL. CARDIOL. ) (United States)  
 2005, 12/1 (12-19)  
 CODEN: JNCAE ISSN: 1071-3581  
 PUBLISHER ITEM IDENTIFIER: S1071358104004593  
 DOCUMENT TYPE: Journal ; Editorial  
 LANGUAGE: ENGLISH  
 NUMBER OF REFERENCES: 46

? ds

Set	Items	Description
S1	33	E5-E8
S2	20	E8-E10
S3	9	(S1 OR S2) AND (CD18 OR CCR2)
S4	8	RD S3 (unique items)
S5	7	(CD18) AND (CCR2) AND (STENOSIS OR RESTENOSIS)
S6	4	RD S5 (unique items)
S7	25	(CD18) (10N) (ANTIBOD? OR ANTAGONI?) AND (STENOSIS OR RESTEN- OSIS)
S8	17	RD S7 (unique items)

? t s8/7/7,12

8/7/7 (Item 1 from file: 73)  
 DIALOG(R) File 73:EMBASE  
 (c) 2007 Elsevier B.V. All rts. reserv.

13087050 EMBASE No: 2005148161  
 Therapeutic intervention in inflammatory diseases: A time and place for anti-adhesion therapy  
 Norman M.U.; Kubes P.  
 Dr. P. Kubes, Department of Physiology/Biophysics, Immunology Research Group, University of Calgary, 3330 Hospital Drive N.W., Calgary, Alta. T2N 4N1 Canada  
 AUTHOR EMAIL: pkubes@ucalgary.ca  
 Microcirculation ( MICROCIRCULATION ) (United States) 2005, 12/1 (91-98)  
 CODEN: MROCE ISSN: 1073-9688  
 DOCUMENT TYPE: Journal ; Review  
 LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
 NUMBER OF REFERENCES: 67

The recruitment of leukocytes from the blood into tissue is central to the development and maintenance of the majority of inflammatory diseases. This multistep process requires a series of leukocyte-endothelial adhesive interactions, involving several families of adhesion molecules. Molecules that block these interactions have been targeted as potential therapeutic treatments for acute and chronic inflammatory diseases. However, many of the anti-adhesion therapy clinical trials have yielded disappointing outcomes. This review discusses some of the animal models that raise questions about the suitability of anti-adhesion therapy to treat certain inflammatory diseases. The authors suggest that it is crucial to understand the underlying mechanisms and timelines of leukocyte recruitment in each affected tissue and inflammatory disease to develop more effective anti-adhesion therapy. Copyright (c) 2005 Taylor & Francis Inc.

8/7/12 (Item 1 from file: 155)  
 DIALOG(R) File 155:MEDLINE(R)  
 (c) format only 2007 Dialog. All rts. reserv.

13089612 PMID: 16100700

Rovelizumab (ICOS Corp).

Jones R

Trinity Cottage, Killiney Hill Road, Killiney, Co Dublin, Ireland,  
rjj101@excite.com

IDrugs - the investigational drugs journal (England) Apr 2000, 3 (4)  
p442-6, ISSN 1369-7056--Print Journal Code: 100883655

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: PubMed not MEDLINE

Rovelizumab is a humanized monoclonal leukointegrin antibody under development by ICOS as a potential treatment for multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke. ICOS announced the commencement of phase II studies in MS patients experiencing acute exacerbations in January 1997; a randomized, double-blind, placebo-controlled phase III trial for acute ischemic stroke, to involve 800 patients, was initiated in January 1999 [312467,313014]. The compound is also undergoing preclinical investigation for cerebral vasospasm, head trauma, kidney transplantation and \*\*\*restenosis\*\*\* [346437]. In September 1999, results from a phase II clinical trial in 45 patients suffering from acute exacerbations of MS were presented at the Warburg Dillion Read Global Life Sciences Conference (New York). The study was designed to evaluate the safety and efficacy of four weekly doses of rovelizumab, as compared to placebo. Rovelizumab was shown to be safe, but demonstrated no clinical benefit for the recovery of neurological functioning [341638]. In February 1997, ICOS announced the initiation of a phase II trial in MI. The placebo-controlled trial is being coordinated by the Mayo Physician Alliance for Cardiovascular Trials and will evaluate safety, pharmacokinetics and infarct size in 60 patients [234046,264363]. Patient enrollment for this, and an open label phase II trial in trauma-induced hemorrhagic shock, was completed in September 1997 [264363]. An expanded shock trial in 150 trauma patients, is expected to complete enrollment by the end of 1998 [296831]. An expanded trial for MI was also planned [264363]. The company is to evaluate rovelizumab in patients with ischemic stroke, and a double-blind, dose-escalating, placebo-controlled phase II trial has been initiated at several centers in the US [264363]. A patient population of 48 was tested, with patient dosing occurring within 12 h of stroke onset symptoms. There was no significant difference in SAEs between rovelizumab and placebo treatment, and no immunogenicity was observed [315799]. Neuroprotection was observed in a rabbit model of focal ischemia, with greatest reduction in infarct noted in the cortical areas of the brain. Neutrophil infiltration to ischemic brain parenchyma was reduced by 90% [315799]. Rovelizumab is a monoclonal \*\*\*antibody\*\*\* directed against the CD11/ \*\*\*CD18\*\*\* cell adhesion proteins. By binding to these receptors, rovelizumab prevents the migration and adhesion of neutrophils in the central nervous system, which may cause brain inflammation and neuronal loss [167725]. Rovelizumab binds to all four known leukointegrin receptors, blocking neutrophil adhesion and binding to ICAMs [307344]. ICOS collaborated with the University of Washington on the preclinical development of this compound [175193].

Record Date Created: 20050815

Record Date Completed: 20050926

? s (ccr2) (10n) (antibod? or antagoni? or inhibit? or suppress? or block?) and (stenosis or restenosis)

Processing

4472	CCR2
2207531	ANTIBOD?
1277282	ANTAGONI?
4882838	INHIBIT?
1014962	SUPPRESS?

1538923 BLOCK?  
727 CCR2(10N) (((ANTIBOD? OR ANTAGONI?) OR INHIBIT?) OR  
SUPPRESS?) OR BLOCK?)  
254561 STENOSIS  
46086 RESTENOSIS  
S9 27 (CCR2)(10N)(ANTIBOD? OR ANTAGONI? OR INHIBIT? OR  
SUPPRESS? OR BLOCK?) AND (STENOSIS OR RESTENOSIS)  
? rd s9  
S10 21 RD S9 (unique items)  
? t s10/3/all

10/3/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2007 The Thomson Corporation. All rts. reserv.

17679639 BIOSIS NO.: 200400060396  
Method of inhibiting stenosis and restenosis  
AUTHOR: Horvath Christopher J (Reprint); Rao Patricia E  
AUTHOR ADDRESS: Taunton, MA, USA\*\*USA  
JOURNAL: Official Gazette of the United States Patent and Trademark Office  
Patents 1277 (3): Dec. 16, 2003 2003  
MEDIUM: e-file  
PATENT NUMBER: US 6663863 PATENT DATE GRANTED: December 16, 2003 20031216  
PATENT CLASSIFICATION: 424-1441 PATENT ASSIGNEE: Millennium  
Pharmaceuticals, Inc. PATENT COUNTRY: USA  
ISSN: 0098-1133 \_(ISSN print)  
DOCUMENT TYPE: Patent  
RECORD TYPE: Abstract  
LANGUAGE: English

10/3/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2007 The Thomson Corporation. All rts. reserv.

17121016 BIOSIS NO.: 200300079735  
Propagermanium, a specific inhibitor of CCR2 chemokine  
receptor, reduces in-stent restenosis in atherosclerotic porcine  
coronary arteries.  
AUTHOR: Matsumoto Yasuharu (Reprint); Uwatoku Toyokazu (Reprint); Abe  
Kohtaro (Reprint); Oi Keiji (Reprint); Hattori Tsuyoshi (Reprint);  
Yokochi Shoji; Hashimoto Hiroyuki; Ishiwata Yoshiro  
AUTHOR ADDRESS: Dept of CV Medicine, Graduate Sch of Medical Science,  
Kyushu Univ, Fukuoka, Japan\*\*Japan  
JOURNAL: Circulation 106 (19 Supplement): pII-217 November 5, 2002 2002  
MEDIUM: print  
CONFERENCE/MEETING: Abstracts from Scientific Sessions Chicago, IL, USA  
November 17-20, 2002; 20021117  
SPONSOR: American Heart Association  
ISSN: 0009-7322 \_(ISSN print)  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Citation  
LANGUAGE: English

10/3/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2007 The Thomson Corporation. All rts. reserv.

16627848 BIOSIS NO.: 200200221359  
Targeting CCR2 or CD18 inhibits experimental in-stent  
restenosis in primates: Inhibitory potential depends on type

of injury and leukocytes targeted  
AUTHOR: Horvath Christopher; Welt Frederick G P (Reprint); Nedelman Mark;  
Rao Patricia; Rogers Campbell  
AUTHOR ADDRESS: Harvard-MIT Division of Health Sciences and Technology,  
MIT, 16-343, Cambridge, MA, 02139, USA\*\*USA  
JOURNAL: Circulation Research 90 (4): p488-494 March 8, 2002 2002  
MEDIUM: print  
ISSN: 0009-7330  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

10/3/4 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2007 Elsevier B.V. All rts. reserv.

12731706 EMBASE No: 2004328920  
Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and  
adaptive immunity: Therapeutic opportunities and controversies  
Daly C.; Rollins B.J.  
B.J. Rollins, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA  
02115 United States  
AUTHOR EMAIL: barret.rollins@dfci.harvard.edu  
Microcirculation ( MICROCIRCULATION ) (United Kingdom) 2003, 10/3-4  
(247-257)  
CODEN: MROCE ISSN: 1073-9688  
DOCUMENT TYPE: Journal ; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 73

10/3/5 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2007 Elsevier B.V. All rts. reserv.

12019305 EMBASE No: 2003130049  
Gene therapy expressing amino-terminal truncated monocyte chemoattractant  
protein-1 prevents renal ischemia-reperfusion injury  
Furuichi K.; Wada T.; Iwata Y.; Kitagawa K.; Kobayashi K.-I.; Hashimoto  
H.; Ishiwata Y.; Tomosugi N.; Mukaida N.; Matsushima K.; Egashira K.;  
Yokoyama H.  
Dr. T. Wada, Department of Gastroenterology, Division of Blood  
Purification, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641  
Japan  
AUTHOR EMAIL: twada@medf.m.kanazawa-u.ac.jp  
Journal of the American Society of Nephrology ( J. AM. SOC. NEPHROL. ) (United States) 01 APR 2003, 14/4 (1066-1071)  
CODEN: JASNE ISSN: 1046-6673  
DOCUMENT TYPE: Journal ; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 27

10/3/6 (Item 3 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2007 Elsevier B.V. All rts. reserv.

11965170 EMBASE No: 2003076273  
Targeting monocyte chemoattractant protein-1 signalling in disease  
Dawson J.; Miltz W.; Mir A.K.; Wiessner C.  
Dr. C. Wiessner, Novartis Pharma AG, Nervous System Research,

Neurodegeneration Unit, CH-4001 Basel Switzerland  
AUTHOR EMAIL: christoph.weissner@pharma.novartis.co  
Expert Opinion on Therapeutic Targets ( EXPERT OPIN. THER. TARGETS ) ( United Kingdom) 2003, 7/1 (35-48)  
CODEN: EOTTA ISSN: 1472-8222  
DOCUMENT TYPE: Journal ; Review  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 137

10/3/7 (Item 1 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

146156231 CA: 146(9)156231v PATENT  
CCR2 inhibitors and methods of use thereof  
INVENTOR(AUTHOR): Ungashe, Solomon; Wright, John J.; Pennell, Andrew M. K.; Wei, Zheng; Melikian, Anita  
LOCATION: USA  
PATENT: U.S. Pat. Appl. Publ. ; US 20070021466 A1 DATE: 20070125  
APPLICATION: US 2006486395 (20060713) \*US 2002PV427670 (20021118) \*US 2003716170 (20031117) \*US 2004846241 (20040513)  
PAGES: 23pp., Cont.-in-part of U.S. Ser. No. 846,241. CODEN: USXXCO  
LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: 514332000  
IPCR/8 + Level Value Position Status Version Action Source Office:  
A61K-0031/444 A I F B 20070101 20070125 H US  
A61K-0031/44 A I L B 20060101 20070125 H US

10/3/8 (Item 2 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

146100558 CA: 146(6)100558q PATENT  
Preparation of arylalkyl-quaternary ammonium salts as chemokine receptor CCR2 antagonists  
INVENTOR(AUTHOR): Lagu, Bharat; Wachter, Michael  
LOCATION: USA  
PATENT: U.S. Pat. Appl. Publ. ; US 20060293379 A1 DATE: 20061228  
APPLICATION: US 2005159018 (20050622)  
PAGES: 95pp. CODEN: USXXCO LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: 514419000  
IPCR/8 + Level Value Position Status Version Action Source Office:  
A61K-0031/405 A I F B 20060101 20061228 H US  
A61K-0031/381 A I L B 20060101 20061228 H US  
A61K-0031/353 A I L B 20060101 20061228 H US  
A61K-0031/165 A I L B 20060101 20061228 H US  
C07D-0409/02 A I L B 20060101 20061228 H US

10/3/9 (Item 3 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

145437241 CA: 145(22)437241s PATENT  
Activity of C-terminal region of CC chemokine receptor 2 and its use for isolating MCP-1 and treating MCP-1/CCR2-associated diseases  
INVENTOR(AUTHOR): Karin, Nathan; Wildbaum, Gizi; Zohar, Yaniv; Izhak, Liat; Weinberg, Uri

LOCATION: Israel

ASSIGNEE: Rappaport Family Institute for Research In the Medical Sciences

PATENT: PCT International ; WO 2006109301 A2 DATE: 20061019

APPLICATION: WO 2006IL454 (20060410) \*US 2005PV671476 (20050415)

PAGES: 73pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

C07K-0014/715 A I F B 20060101 H EP

C07K-0014/52 A I L B 20060101 H EP

C12N-0015/62 A I L B 20060101 H EP

A61K-0038/16 A I L B 20060101 H EP

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

10/3/10 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2007 American Chemical Society. All rts. reserv.

145145555 CA: 145(8)145555g PATENT

Preparation of aryl and heteroaryl sulfonamides as CCR2 antagonists

INVENTOR(AUTHOR): Ungashe, Solomon

LOCATION: USA

ASSIGNEE: Chemocentryx, Inc.

PATENT: PCT International ; WO 200676644 A2 DATE: 20060720

APPLICATION: WO 2006US1341 (20060113) \*US 2005PV644103 (20050114) \*US 2005PV742821 (20051206) \*US 2005PV750985 (20051216)

PAGES: 270 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0031/496 A I F B 20060101 H US

A61K-0031/4545 A I L B 20060101 H US

C07D-0403/02 A I L B 20060101 H US

C07D-0401/02 A I L B 20060101 H US

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

10/3/11 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2007 American Chemical Society. All rts. reserv.

144350550 CA: 144(19)350550x PATENT

Substituted dipiperidines as CCR2 antagonists, their preparation, pharmaceutical compositions, and use in therapy

INVENTOR(AUTHOR): Xia, Mingde; Wachter, Michael P.; Pan, Meng; Demong,

Duane E.; Pollack, Scott R.

LOCATION: USA

PATENT: U.S. Pat. Appl. Publ. ; US 20060069123 A1 DATE: 20060330

APPLICATION: US 2005224215 (20050912) \*US 2004PV613922 (20040928)

PAGES: 131 pp. CODEN: USXXCO LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: 514316000

IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0031/4545 A I F B 20060101 20060330 H US

C07D-0403/14 A I L B 20060101 20060330 H US

10/3/12 (Item 6 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2007 American Chemical Society. All rts. reserv.

143115432 CA: 143(7)115432f PATENT

Preparation of 3-cycloalkylaminopyrrolidine chemokine receptor antagonists as antiinflammatory and immunomodulatory bioactive compounds

INVENTOR(AUTHOR): Xue, Chu-Biao; Metcalf, Brian; Han, Amy Qi; Robinson, Darius J.; Zheng, Changsheng; Wang, Anlai; Zhang, Yingxin

LOCATION: USA

ASSIGNEE: Incyte Corporation

PATENT: PCT International ; WO 200560665 A2 DATE: 20050707

APPLICATION: WO 2004US42321 (20041216) \*US 2003PV531270 (20031218)

PAGES: 151 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

10/3/13 (Item 7 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2007 American Chemical Society. All rts. reserv.

142297977 CA: 142(16)297977x PATENT

Preparation of N-acylated 1,2-diamino-3-hydroxyhexanes as modulators of CCR2 chemokine receptor activity

INVENTOR(AUTHOR): Carter, Percy H.

LOCATION: USA

ASSIGNEE: Bristol-Myers Squibb Company

PATENT: PCT International ; WO 200521499 A1 DATE: 20050310

APPLICATION: WO 2004US27379 (20040820) \*US 2003PV496775 (20030821)

PAGES: 215 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C07D-205/04A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;

BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL;  
PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR;  
NE; SN; TD; TG

10/3/14 (Item 8 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

142196523 CA: 142(11)196523r PATENT  
Antibodies bind to sulfated epitopes involving cell rolling, metastasis,  
inflammation, viral entry and autoimmune disease for diagnosis, prognosis  
and therapy  
INVENTOR(AUTHOR): Plaksin, Daniel; Levanon, Avigdor; Szanton, Esther;  
Hagay, Yocheved; Ben-Levy, Rachel; Nisgav, Yael; Szrajber, Tali; Kanfi,  
Yariv  
LOCATION: USA  
ASSIGNEE: Savient Pharmaceuticals, Inc.  
PATENT: PCT International ; WO 200510153 A2 DATE: 20050203  
APPLICATION: WO 2004US21002 (20040630) \*US 2003611238 (20030630)  
PAGES: 134 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: C12N-000/A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;  
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;  
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;  
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ  
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;  
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL;  
PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR;  
NE; SN; TD; TG

10/3/15 (Item 9 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

141054188 CA: 141(4)54188r PATENT  
Preparation of 3-aminopyrrolidine chemokine receptor antagonists as  
antiinflammatory and immunomodulatory bioactive compounds  
INVENTOR(AUTHOR): Xue, Chu-Biao; Metcalf, Brian; Feng, Hao; Cao, Ganfeng;  
Huang, Taisheng; Zheng, Changsheng; Robinson, Darius J.; Han, Amy Qi  
LOCATION: USA  
ASSIGNEE: Incyte Corporation  
PATENT: PCT International ; WO 200450024 A2 DATE: 20040617  
APPLICATION: WO 2003US37946 (20031126) \*US PV429605 (20021127) \*US  
PV463976 (20030418)  
PAGES: 221 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-000/A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;  
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;  
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE;  
SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW  
DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM;  
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE;  
ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF; BJ;  
CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG



10/3/16 (Item 10 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

139164702 CA: 139(11)164702v PATENT  
Preparation of pyrrolidinone and pyrrolidine-thiones as CCR2 antagonists  
INVENTOR(AUTHOR): Zou, Dong; Dasse, Olivier; Evans, Janelle; Higgins,  
Paul; Kintigh, Jeremy; Kondru, Rama; Schwartz, Eric; Knerr, Laurent; Zhai,  
Hai-xiao  
LOCATION: USA  
PATENT: U.S. Pat. Appl. Publ. ; US 20030149081 A1 DATE: 20030807  
APPLICATION: US 255494 (20020926) \*US 970140 (20011003) \*US PV400807  
(20020801)  
PAGES: 19 pp., Cont.-in-part of U.S. Ser. No. 970,140. CODEN: USXXCO  
LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: 514343000; A61K-031/4439A; A61K-031/4015B; C07D-043/02B;  
C07D-207/273B

10/3/17 (Item 11 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

137232638 CA: 137(16)232638q PATENT  
Preparation of bicyclic diamines as CCR2 and CCR3 chemokine receptor  
antagonists for treating/preventing diseases associated with monocyte,  
lymphocyte or leukocyte accumulation  
INVENTOR(AUTHOR): Colon-Cruz, Roberto; Didiuk, Mary Theresa; Duffy, Erin  
Maureen; Garigipati, Ravi Shanker; Lau, Wan Fang; McDonald, Wayne Scott  
LOCATION: USA  
ASSIGNEE: Pfizer Products Inc.  
PATENT: PCT International ; WO 200270523 A1 DATE: 20020912  
APPLICATION: WO 2002IB238 (20020124) \*US PV273984 (20010307)  
PAGES: 165 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: C07D-487/04A; A61K-031/407B; A61P-029/00B  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;  
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;  
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE;  
SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZM; ZW;  
AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW;  
; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB;  
GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;  
ML; MR; NE; SN; TD; TG

10/3/18 (Item 12 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

137168272 CA: 137(12)168272m PATENT  
Antibodies and fragments specific to CD18 antigen or chemokine receptor  
CCR2 for inhibiting stenosis and restenosis  
INVENTOR(AUTHOR): Horvath, Christopher J.; Rao, Patricia E.  
LOCATION: USA  
ASSIGNEE: Millennium Pharmaceuticals, Inc.  
PATENT: U.S. Pat. Appl. Publ. ; US 20020106369 A1 DATE: 20020808  
APPLICATION: US 809739 (20010315) \*US 528267 (20000317)  
PAGES: 59 pp., Cont.-in-part of U. S. Ser. No. 528,267, abandoned.

CODEN: USXXCO LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: 424131100; A61K-039/395A

10/3/19 (Item 13 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

136231240 CA: 136(15)231240w PATENT  
Anti-CCR2 antibodies, fragments and labeled derivatives for treatment,  
diagnosis and prophylaxis of restenosis and inflammatory diseases  
INVENTOR(AUTHOR): Larosa, Gregory J.; Horvath, Christopher; Newman,  
Walter  
LOCATION: USA  
ASSIGNEE: Millennium Pharmaceuticals, Inc.  
PATENT: United States ; US 6352832 B1 DATE: 20020305  
APPLICATION: US 359193 (19990722) \*US 121781 (19980723)  
PAGES: 37 pp., Cont.-in-part of U. S. Ser. No. 121,781. CODEN: USXXAM  
LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: 435007100; G01N-033/53A

10/3/20 (Item 14 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

135283193 CA: 135(20)283193g PATENT  
Method of inhibiting stenosis and restenosis using CD18 or CCR2  
antibodies  
INVENTOR(AUTHOR): Horvath, Christopher J.; Rao, Patricia E.  
LOCATION: USA  
ASSIGNEE: Millennium Pharmaceuticals, Inc.  
PATENT: PCT International ; WO 200170266 A2 DATE: 20010927  
APPLICATION: WO 2001US8266 (20010315) \*US 528267 (20000317)  
PAGES: 108 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-039/395A; A61P-009/10B  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM;  
HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV;  
MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK;  
SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD;  
RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG  
; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT;  
SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

10/3/21 (Item 15 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

135179711 CA: 135(13)179711p PATENT  
Humanized anti mammalian CC-chemokine receptor 2 (CCR2) antibodies and  
uses in therapeutics, prophylaxis and diagnosis  
INVENTOR(AUTHOR): Larosa, Gregory J.; Horvath, Christopher; Newman,  
Walter; Jones, S. Tarran; O'Brien, Siobhan; O'Keefe, Theresa  
LOCATION: USA  
ASSIGNEE: Millennium Pharmaceuticals, Inc.  
PATENT: PCT International ; WO 200157226 A1 DATE: 20010809  
APPLICATION: WO 2001US3537 (20010202) \*US 497625 (20000203)

PAGES: 185 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C12N-015/62A; C07K-016/28B; C07K-016/46B; C12N-015/13B;  
C12N-015/63B; C12N-005/10B; A61K-039/395B; A61P-009/10B; A61P-019/02B;  
A61P-031/18B; A61P-037/06B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR;  
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA;  
MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL;  
TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD;  
RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG  
; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT;  
SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG  
?

ds

Set	Items	Description
S1	33	E5-E8
S2	20	E8-E10
S3	9	(S1 OR S2) AND (CD18 OR CCR2)
S4	8	RD S3 (unique items)
S5	7	(CD18) AND (CCR2) AND (STENOSIS OR RESTENOSIS)
S6	4	RD S5 (unique items)
S7	25	(CD18) (10N) (ANTIBOD? OR ANTAGONI?) AND (STENOSIS OR RESTEN- OSIS)
S8	17	RD S7 (unique items)
S9	27	(CCR2) (10N) (ANTIBOD? OR ANTAGONI? OR INHIBIT? OR SUPPRESS? OR BLOCK?) AND (STENOSIS OR RESTENOSIS)
S10	21	RD S9 (unique items)

? s s10 and py<2001  
Processing  
Processing

21	S10
52594809	PY<2001
S11	0 S10 AND PY<2001

? s (cd18) (10n) (antibod? or antagoni? or inhibit? or suppress? or block?) and  
(stenosis or restenosis)  
Processing

16710	CD18
2207531	ANTIBOD?
1277282	ANTAGONI?
4882838	INHIBIT?
1014962	SUPPRESS?
1538923	BLOCK?
5761	CD18 (10N) (((ANTIBOD? OR ANTAGONI?) OR INHIBIT?) OR SUPPRESS?) OR BLOCK?)
254561	STENOSIS
46086	RESTENOSIS
S12	30 (CD18) (10N) (ANTIBOD? OR ANTAGONI? OR INHIBIT? OR SUPPRESS? OR BLOCK?) AND (STENOSIS OR RESTENOSIS)

? rd s12  
S13 20 RD S12 (unique items)  
? t s13/3/all

13/3/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2007 The Thomson Corporation. All rts. reserv.

17679639 BIOSIS NO.: 200400060396  
Method of inhibiting stenosis and restenosis  
AUTHOR: Horvath Christopher J (Reprint); Rao Patricia E  
AUTHOR ADDRESS: Taunton, MA, USA\*\*USA  
JOURNAL: Official Gazette of the United States Patent and Trademark Office  
Patents 1277 (3): Dec. 16, 2003 2003  
MEDIUM: e-file  
PATENT NUMBER: US 6663863 PATENT DATE GRANTED: December 16, 2003 20031216  
PATENT CLASSIFICATION: 424-1441 PATENT ASSIGNEE: Millennium  
Pharmaceuticals, Inc. PATENT COUNTRY: USA  
ISSN: 0098-1133 (ISSN print)  
DOCUMENT TYPE: Patent  
RECORD TYPE: Abstract  
LANGUAGE: English

13/3/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

16627848 BIOSIS NO.: 200200221359  
Targeting CCR2 or CD18 inhibits experimental in-stent  
restenosis in primates: Inhibitory potential depends on type  
of injury and leukocytes targeted  
AUTHOR: Horvath Christopher; Welt Frederick G P (Reprint); Nedelman Mark;  
Rao Patricia; Rogers Campbell  
AUTHOR ADDRESS: Harvard-MIT Division of Health Sciences and Technology,  
MIT, 16-343, Cambridge, MA, 02139, USA\*\*USA  
JOURNAL: Circulation Research 90 (4): p488-494 March 8, 2002 2002  
MEDIUM: print  
ISSN: 0009-7330  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

13/3/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2007 The Thomson Corporation. All rts. reserv.

15896967 BIOSIS NO.: 200100068806  
Targeting CCR-2 or CD18 inhibits experimental in-stent  
\*\*\*restenosis\*\*\* in primates. \*\*\*Inhibitory\*\*\* potential depends on type  
of injury and leukocytes targeted  
AUTHOR: Welt Frederick G P (Reprint); Horvath Christopher; Nedelman Mark;  
Rao Patricia; Rogers Campbell  
AUTHOR ADDRESS: Brigham and Women's Hosp, Boston, MA, USA\*\*USA  
JOURNAL: Circulation 102 (18 Supplement): pII.247 October 31, 2000 2000  
MEDIUM: print  
CONFERENCE/MEETING: Abstracts from American Heart Association Scientific  
Sessions 2000 New Orleans, Louisiana, USA November 12-15, 2000; 20001112  
SPONSOR: American Heart Association  
ISSN: 0009-7322  
DOCUMENT TYPE: Meeting; Meeting Poster  
RECORD TYPE: Citation  
LANGUAGE: English

13/3/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2007 The Thomson Corporation. All rts. reserv.

15819149 BIOSIS NO.: 200000537462  
Anti-CD18 antibody blocks leucocyte trafficking in  
porcine coronary arteries following PTCA  
AUTHOR: Malik N (Reprint); Holt C M; Gunn J; Hellewell P; Cumberland D C;  
Crossman D C  
AUTHOR ADDRESS: Cardiovascular Research Group, Northern General Hospital,  
Sheffield, UK\*\*UK  
JOURNAL: European Heart Journal 21 (Abstract Supplement): p284  
August-September, 2000 2000  
MEDIUM: print  
CONFERENCE/MEETING: XXII Congress of the European Society of Cardiology  
Amsterdam, Netherlands August 26-30, 2000; 20000826  
SPONSOR: European Society of Cardiology  
ISSN: 0195-668X  
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster  
RECORD TYPE: Citation  
LANGUAGE: English

13/3/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2007 The Thomson Corporation. All rts. reserv.

13910318 BIOSIS NO.: 199799544378  
Inhibition of leucocyte and platelet adhesion reduces neointimal  
hyperplasia after arterial injury  
AUTHOR: Golino Paolo (Reprint); Ambrosio Giuseppe; Ragni Massimo; Cirillo  
Plinio; Esposito Nicolino; Willerson James T; Rothlein Robert; Petrucci  
Luisa; Condorelli Mario; Chiareillo Massimo; Buja L Maximilan  
AUTHOR ADDRESS: Div. Cardiol., 2nd Sch. Med., Univ. Naples, Via S. Pansini  
5, 80131 Naples, Italy\*\*Italy  
JOURNAL: Thrombosis and Haemostasis 77 (4): p783-788 1997 1997  
ISSN: 0340-6245  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

13/3/6 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2007 The Thomson Corporation. All rts. reserv.

13160645 BIOSIS NO.: 199698628478  
Role of leukocytes in neointimal formation after balloon angioplasty in the  
rabbit atherosclerotic model  
AUTHOR: Guzman Luis A; Forudi Farhad; Villa Augusto E; Topol Eric J  
(Reprint)  
AUTHOR ADDRESS: Cleveland Clin. Foundation, 9500 Euclid Ave., Desk F-25,  
Cleveland, OH 44195-5066, USA\*\*USA  
JOURNAL: Coronary Artery Disease 6 (9): p693-701 1995 1995  
ISSN: 0954-6928  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

13/3/7 (Item 7 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2007 The Thomson Corporation. All rts. reserv.

12193575 BIOSIS NO.: 199497214860  
Effect of anti-CD18 adhesion glycoprotein monoclonal antibody  
on restenosis following balloon angioplasty in the rabbit  
atherosclerosis model  
AUTHOR: Guzman Luis A; Villa Augusto E; Forudi Farhad; Rothlein Robert;  
Topol Eric J  
AUTHOR ADDRESS: Cleve. Clin. Found., Cleveland, OH, USA\*\*USA  
JOURNAL: Journal of the American College of Cardiology 0 (SPEC. ISSUE): p  
20A 1994 1994  
CONFERENCE/MEETING: 43rd Annual Scientific Session of the American College  
of Cardiology Atlanta, Georgia, USA March 13-17, 1994; 19940313  
ISSN: 0735-1097  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Citation  
LANGUAGE: English

13/3/8 (Item 8 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2007 The Thomson Corporation. All rts. reserv.

11194133 BIOSIS NO.: 199293037024  
ROLE OF GRANULOCYTES IN ENDOTHELIAL INJURY IN CORONARY HEART DISEASE IN  
HUMANS  
AUTHOR: RICEVUTI G (Reprint); MAZZONE A; PASOTTI D; DE SERVI S; SPECCHIA G  
AUTHOR ADDRESS: IST PATOLOGIA MED I, UNIV PAVIA, IRCCS POLICLINICO SAN  
MATTEO, PIAZZALE GOLGI 2, 27100, IRCCS PLICLINICO SAN MATTEO, PIAZZLE  
GOLGI 2, 27100 PAVIA, ITALY\*\*ITALY  
JOURNAL: Atherosclerosis 91 (1-2): p1-14 1991  
ISSN: 0021-9150  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

13/3/9 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2007 Elsevier B.V. All rts. reserv.

13087050 EMBASE No: 2005148161  
Therapeutic intervention in inflammatory diseases: A time and place for  
anti-adhesion therapy  
Norman M.U.; Kubes P.  
Dr. P. Kubes, Department of Physiology/Biophysics, Immunology Research  
Group, University of Calgary, 3330 Hospital Drive N.W., Calgary, Alta.  
T2N 4N1 Canada  
AUTHOR EMAIL: pkubes@ucalgary.ca  
Microcirculation ( MICROCIRCULATION ) (United States) 2005, 12/1  
(91-98)  
CODEN: MROCE ISSN: 1073-9688  
DOCUMENT TYPE: Journal ; Review  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 67

13/3/10 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2007 Elsevier B.V. All rts. reserv.

12990559 EMBASE No: 2005050598  
Tc-99m sestamibi infarct size as a surrogate endpoint  
Gibbons R.J.; Miller T.D.  
Dr. R.J. Gibbons, Nuclear Cardiology Laboratory, Mayo Clinic, 200 First  
St. SW, Rochester, MN 55905 United States  
AUTHOR EMAIL: gibbons.raymond@mayo.edu  
Journal of Nuclear Cardiology ( J. NUCL. CARDIOL. ) (United States)  
2005, 12/1 (12-19)  
CODEN: JNCAE ISSN: 1071-3581  
PUBLISHER ITEM IDENTIFIER: S1071358104004593  
DOCUMENT TYPE: Journal ; Editorial  
LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 46

13/3/11 (Item 3 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2007 Elsevier B.V. All rts. reserv.

12217567 EMBASE No: 2003330343  
Adhesion of monocytes to medical steel as used for vascular stents is  
mediated by the integrin receptor Mac-1 (CD11b/CD18; alphaSUBM  
betaSUB2) and can be inhibited by semiconductor coating

Schuler P.; Assefa D.; Ylanne J.; Basler N.; Olschewski M.; Ahrens I.; Nordt T.; Bode C.; Peter K.  
Dr. K. Peter, Department of Cardiology/Angiology, University of Freiburg, Hugstetter Str. 55, 79106 Freiburg Germany  
AUTHOR EMAIL: peterkh@medizin.ukl.uni-freiburg.de  
Cell Communication and Adhesion ( CELL COMMUN. ADHES. ) (United States) 2003, 10/1 (17-26)  
CODEN: CCAEB ISSN: 1541-9061  
DOCUMENT TYPE: Journal ; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 32

13/3/12 (Item 4 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2007 Elsevier B.V. All rts. reserv.

07410615 EMBASE No: 1998305613  
A mAb to the betainf 2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits  
Rogers C.; Edelman E.R.; Simon D.I.  
C. Rogers, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115 United States  
AUTHOR EMAIL: cdrogers@bics.bwh.harvard.edu  
Proceedings of the National Academy of Sciences of the United States of America ( PROC. NATL. ACAD. SCI. U. S. A. ) (United States) 18 AUG 1998, 95/17 (10134-10139)  
CODEN: PNAS ISSN: 0027-8424  
DOCUMENT TYPE: Journal; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 58

13/3/13 (Item 1 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2007 Dialog. All rts. reserv.

14413817 PMID: 12881037  
Adhesion of monocytes to medical steel as used for vascular stents is mediated by the integrin receptor Mac-1 (CD11b/CD18; alphaM beta2) and can be \*\*\*inhibited\*\*\* by semiconductor coating.  
Schuler Pia; Assefa Dawit; Ylanne Jari; Basler Nicole; Olschewski Manfred; Ahrens Ingo; Nordt Thomas; Bode Christoph; Peter Karlheinz  
Department of Cardiology and Angiology, University of Freiburg, Freiburg, Germany.  
Cell communication & adhesion (England) Jan-Feb 2003, 10 (1) p17-26, ISSN 1541-9061--Print Journal Code: 101096596  
Publishing Model Print  
Document type: Journal Article  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

13/3/14 (Item 2 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2007 Dialog. All rts. reserv.

13089612 PMID: 16100700  
Rovelizumab (ICOS Corp).  
Jones R  
Trinity Cottage, Killiney Hill Road, Killiney, Co Dublin, Ireland,



rjj101@excite.com

IDrugs - the investigational drugs journal (England) Apr 2000, 3 (4)  
p442-6, ISSN 1369-7056--Print Journal Code: 100883655  
Publishing Model Print  
Document type: Journal Article  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: PubMed not MEDLINE

13/3/15 (Item 3 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)  
(c) format only 2007 Dialog. All rts. reserv.

11881678 PMID: 9707613

A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits.

Rogers C; Edelman E R; Simon D I

Department of Medicine, Cardiac Catheterization Laboratory and Coronary Care Unit, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. cdrogers@bics.bwh.harvard.edu

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Aug 18 1998, 95 (17) p10134-9, ISSN 0027-8424  
--Print Journal Code: 7505876

Contract/Grant No.: GM/HL49039; GM; NIGMS; HL02768; HL; NHLBI; HL03104; HL; NHLBI; +

Publishing Model Print  
Document type: Journal Article  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

13/3/16 (Item 4 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)  
(c) format only 2007 Dialog. All rts. reserv.

11808972 PMID: 9633931

Role of polymorphonuclear leukocytes in collar-induced intimal thickening in the rabbit carotid artery.

Van Put D J; Van Osselaer N; De Meyer G R; Andries L J; Kockx M M; De Clerck L S; Bult H

Division of Pharmacology, University of Antwerp (UIA), Wilrijk, Belgium.  
Arteriosclerosis, thrombosis, and vascular biology (UNITED STATES) Jun 1998, 18 (6) p915-21, ISSN 1079-5642--Print Journal Code: 9505803

Publishing Model Print  
Document type: Journal Article  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

13/3/17 (Item 1 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

137168272 CA: 137(12)168272m PATENT

Antibodies and fragments specific to CD18 antigen or chemokine receptor CCR2 for inhibiting stenosis and restenosis

INVENTOR(AUTHOR): Horvath, Christopher J.; Rao, Patricia E.

LOCATION: USA

ASSIGNEE: Millennium Pharmaceuticals, Inc.

PATENT: U.S. Pat. Appl. Publ. ; US 20020106369 A1 DATE: 20020808  
APPLICATION: US 809739 (20010315) \*US 528267 (20000317)  
PAGES: 59 pp., Cont.-in-part of U. S. Ser. No. 528,267, abandoned.  
CODEN: USXXCO LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: 424131100; A61K-039/395A

13/3/18 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

135283193 CA: 135(20)283193g PATENT  
Method of inhibiting stenosis and restenosis using CD18 or CCR2  
antibodies  
INVENTOR(AUTHOR): Horvath, Christopher J.; Rao, Patricia E.  
LOCATION: USA  
ASSIGNEE: Millennium Pharmaceuticals, Inc.  
PATENT: PCT International ; WO 200170266 A2 DATE: 20010927  
APPLICATION: WO 2001US8266 (20010315) \*US 528267 (20000317)  
PAGES: 108 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-039/395A; A61P-009/10B  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM;  
HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV;  
MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK;  
SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD;  
RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG  
; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT;  
SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

13/3/19 (Item 3 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

135271896 CA: 135(19)271896a PATENT  
CD18-binding antibodies inhibit stenosis-related disorders  
INVENTOR(AUTHOR): Horvath, Christopher J.  
LOCATION: USA  
ASSIGNEE: Millennium Pharmaceuticals, Inc.  
PATENT: PCT International ; WO 200170260 A1 DATE: 20010927  
APPLICATION: WO 2001US8383 (20010316) \*US 531088 (20000317)  
PAGES: 80 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-039/00A; A61K-039/395B; C07K-016/00B; C07K-016/28B  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM;  
HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV;  
MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK;  
SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD;  
RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG  
; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT;  
SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

13/3/20 (Item 4 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

129254997 CA: 129(20)254997t PATENT

Modulation of vascular healing by inhibition of leukocyte adhesion and function

INVENTOR(AUTHOR): Rogers, Campbell; Edelman, Elazer R.; Simon, Daniel I.

LOCATION: USA

ASSIGNEE: Massachusetts Institute of Technology; Brigham and Women's Hospital, Inc.

PATENT: PCT International ; WO 9842360 A1 DATE: 19981001

APPLICATION: WO 98US5841 (19980325) \*US 823999 (19970325)

PAGES: 31 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-038/00A; C07K-014/705B

DESIGNATED COUNTRIES: CA; JP DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES  
; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE

?